Why the study?
Vessel co-option in colorectal cancer liver metastases is linked to poor response to anti-angiogenic therapy, and the role of host angiopoietin1 expression in supporting this process required investigation.
Does Ang1 deficiency in hepatocytes affect the growth and histopathological growth pattern of colorectal cancer liver metastases?
Does Ang1 deficiency in hepatocytes affect the growth and histopathological growth pattern of colorectal cancer liver metastases?
High expression of Ang1 in the host liver supports vessel co-option in colorectal cancer liver metastases, and its inhibition favors the formation of angiogenic-driven lesions.
Answers are grounded in this paper and cite their sources.
Ang1 expression in co-opting CRCLM may warrant target exploration; animal data leave open clinical translation to anti-angiogenic strategies.
Colorectal cancer liver metastases (CRCLM) that receive their blood supply via vessel co-option are associated with a poor response to anti-angiogenic therapy. Angiopoietins (Ang1 and Ang2) with their Tyrosine-protein kinase receptor (Tie2) have been shown to support vessel co-option. We demonstrate significantly higher expression of Ang1 in hepatocytes adjacent to the tumor region of human chemonaïve and treated co-opting (replacement histopathological growth patterns: RHGP) tumors. To investigate the role of the host Ang1 expression, Ang1 knockout (KO) mice were injected intra-splenically with metastatic MC-38 colon cancer cells that develop co-opting liver metastases. We observed a reduction in the number of liver metastases and interestingly, for the first time, the development of angiogenic driven desmoplastic (DHGP) liver metastases. In addition, in-vitro, knockout of Ang1 in primary hepatocytes inhibited viability, migration and invasion ability of MC-38 cells. We also demonstrate that Ang 1 alone promotes the migration and growth of both human and mouse colon cancer cell lines These results provide evidence that high expression of Ang1 in the host liver is important to support vessel co-option (RHGP lesions) and when inhibited, favours the formation of angiogenic driven liver metastases (DHGP lesions).
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: